Literature DB >> 8835779

Uptake and distribution of fluorescein-labeled D2 dopamine receptor antisense oligodeoxynucleotide in mouse brain.

S P Zhang1, L W Zhou, M Morabito, R C Lin, B Weiss.   

Abstract

To determine the uptake and distribution of oligodeoxynucleotides in brain, a 20-mer phosphorothioated oligodeoxynucleotide complementary to a portion of the D2 dopamine receptor mRNA was fluorescently labeled with fluorescein isothiocyanate (FITC) and injected into the lateral cerebral ventricles of mice. At various survival times after the injection, the brains were removed, fixed, sectioned, and viewed under a fluorescent microscope. The results showed that the oligodeoxynucleotide was rapidly taken up into the brain. Initially the label was relatively diffusely spread throughout the interstitial spaces of the brain, then became redistributed to the cellular compartments. The signal extended from those forebrain nuclei located immediately in contact with the ventricles, such as the corpus striatum, septum, and hippocampus, to areas further removed from the ventricles, such as the cerebral cortex, nucleus accumbens, and substantia nigra. When the FITC-labeled D2 antisense oligodeoxynucleotide was given once daily for 4 d, the signal intensity seen 24 h after the last injection appeared to be of greater intensity overall compared to that seen after a single injection. At early time-points the oligodeoxynucleotide signals appeared to be punctuated and were found in cell bodies as well as in proximal dendritic processes. However, not all cells were equally labeled, suggesting an uneven uptake and accumulation of the D2 antisense into the various cell types. At later time-points the fluorescent signal appeared granular; at these times the injected material was largely degraded. These studies show that a D2 dopamine receptor antisense oligodeoxynucleotide is rapidly taken up from cerebral ventricles into brain, becomes widely distributed throughout the brain tissue to areas far removed from direct contact with the ventricles, and appears to accumulate to a different extent in the various brain areas and cell types.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8835779     DOI: 10.1007/BF02736845

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  37 in total

Review 1.  ANTISENSE oligonucleotides: a new tool in neuroscience.

Authors:  P M Pilowsky; S Suzuki; J B Minson
Journal:  Clin Exp Pharmacol Physiol       Date:  1994-12       Impact factor: 2.557

2.  Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system.

Authors:  L Whitesell; D Geselowitz; C Chavany; B Fahmy; S Walbridge; J R Alger; L M Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

3.  Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake.

Authors:  X M Lu; A J Fischman; S L Jyawook; K Hendricks; R G Tompkins; M L Yarmush
Journal:  J Nucl Med       Date:  1994-02       Impact factor: 10.057

4.  Characterization of oligonucleotide transport into living cells.

Authors:  S L Loke; C A Stein; X H Zhang; K Mori; M Nakanishi; C Subasinghe; J S Cohen; L M Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor.

Authors:  K M Standifer; C C Chien; C Wahlestedt; G P Brown; G W Pasternak
Journal:  Neuron       Date:  1994-04       Impact factor: 17.173

6.  Cellular uptake of phosphorothioate oligodeoxynucleotides is negatively affected by cell density in a transformed rat tracheal epithelial cell line: implication for antisense approaches.

Authors:  T Iwanaga; P C Ferriola
Journal:  Biochem Biophys Res Commun       Date:  1993-03-31       Impact factor: 3.575

Review 7.  Pharmacokinetics of antisense oligonucleotides.

Authors:  S Agrawal; J Temsamani; W Galbraith; J Tang
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 8.  Modified oligonucleotides as therapeutic and diagnostic agents.

Authors:  S Agrawal; R P Iyer
Journal:  Curr Opin Biotechnol       Date:  1995-02       Impact factor: 9.740

9.  Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain.

Authors:  S Ogawa; H E Brown; H J Okano; D W Pfaff
Journal:  Regul Pept       Date:  1995-10-20

10.  Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

Authors:  A R Thierry; A Dritschilo
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

View more
  1 in total

1.  Use of a mu-antisense oligodeoxynucleotide as a mu opioid receptor noncompetitive antagonist in vivo.

Authors:  X H Chen; L Y Liu-Chen; R J Tallarida; E B Geller; J K de Riel; M W Adler
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.